Dr. Henriqueta Louro

National Institute of Health Dr Ricardo Jorge, Portugal

Dr. Henriqueta Louro graduated in Biochemistry (Faculty of Sciences, University of Lisbon) and has a Ph.D. in Public Health (National School of Public Health, NOVA University of Lisbon). She is also specialist in Human Genetics (Portuguese Ministry of Health) and works as Principal Research Scientist at the Department of Human Genetics of the National Institute of Health Dr. Ricardo Jorge (INSA), in Lisbon, Portugal, in the field of genetic toxicology. She is an integrated researcher at the Comprehensive Health Research Centre (CHRC, NOVA Medical School, Lisbon).

Her research focuses on genotoxicity, nanotoxicology and human biomonitoring, with participation in nationally funded projects and hallmark European initiatives, such as Nanogenotox, Nanoreg, and HBM4EU and currently in European Partnership for the Assessment of Risks from Chemicals (PARC; 2022–2029), were she takes responsibilities as task leader. Her work has been published in more than 100 peer reviewed international journals and scientific books, and more than 120 conference communications.

Dr Louro is the nominated Head of the Portuguese Delegation to the OECD Working Party on Manufactured Nanomaterials and, since 2015, she is a member of the Portuguese ISO/CEN Technical Commission for Nanotechnologies (CT194). She was involved in the OECD project on the use of Adverse Outcome Pathways (AOPs) to address combined chemical exposures with effect biomarkers and ACA/ELCA project.

Collaborates with the European Food Safety Authority as a member of the Panel on Food Additives and Flavourings, and of the cross-cutting Working Groups on Genotoxicity, on Nanotechnologies, and on NAMs. She also serves as a Genotoxicity expert for the European Scientific Committee on Consumer Safety (SCCS), participating in the Working Groups on Cosmetic Ingredients and on Nanomaterials in Cosmetic Products. Furthermore, she collaborates with the Joint FAO/WHO Expert Committee on Food Additives (JECFA) and has contributed to working groups of the International Agency for Research on Cancer (IARC/WHO) Monographs Programme.